Treatments

*October 2021* Purpose: This study aimed to explore the clinical value of SBRT for primary lung lesions of EGFR-mutant NSCLC patients with non-oligometastatic disease during first-line EGFR-TKI treatment. Methods: We identified patients with stage IV EGFR-mutant non-oligometastatic NSCLC who were suitable to receive SBRT for the primary tumors after EGFR-TKI treatment. All…

*October 2021* The understanding of EGFR signaling in non–small cell lung cancer (NSCLC) continues to evolve, helping to spark the development of novel therapies for new patient populations with uncommon alterations. In May, the FDA granted an accelerated approval to amivantamab-vmjw (Rybrevant) for patients with locally advanced or metastatic NSCLC…

*October 2021* Sintilimab with or without a bevacizumab biosimilar injection, combined with chemotherapy yielded promising findings in a population of patients with EGFR-mutant nonsquamous non–small cell lung cancer who have previously been treated with an EGFR tyrosine kinase inhibitor. Sintilimab (Tyvyt) has yielded a promising improvement to progression-free survival (PFS)…

*July 2021* Highlights Pemetrexed-carbo plus bevacizumab and atezolizumab was effective in EGFR mutated lung cancer. Median PFS of 9.4 months, 1 year OS 72.5% in this heavily pretreated population were remarkable. Having similar efficacy, this regimen gave less toxicity compared with IMPower150 regimen. QoL was well preserved in patients which used pemetrexed…

*October 2021* Several small molecule EGFR tyrosine kinase inhibitors (TKIs) are now available for the treatment of EGFR-mutated non–small cell lung cancer (NSCLC). However, progression after TKI therapy—including with the third-generation TKI osimertinib (Tagrisso)—is inevitable. Results of several studies targeting new treatment strategies were reported at the recent International Association for…

*October 2021* For people with lung cancer, drug resistance is the major cause of relapse. A tumor might respond very well at first — maybe even shrinking down to an undetectable level — only to develop resistance and grow back. Scientists are learning that one of the ways that lung cancers…

*November 2021* Note: We have been told that there is travel reimbursement for this trial, both for the patient and the caregiver — so interested parties should not be deterred due to travel expenses and should contact the individual trial locations/contacts to learn more. From Blueprint Medicines: Currently, there are no…

*September 2021* Results from the IMpower133 and CASPIAN trials gave the small-cell lung cancer (SCLC) community something to cheer about: Both studies showed benefit with add-on PD-L1 blockade -- atezolizumab (Tecentriq) and durvalumab (Imfinzi), respectively -- and both of those agents are now part of front-line SCLC care. But initial…

*September 2021* Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are established driver mutations in non-small cell lung cancer (NSCLC)1,2,3. Targeted therapies are approved for patients with ‘classical’ mutations and a small number of other mutations4,5,6. However, effective therapies have not been identified for additional EGFR mutations. Furthermore,…